StockUS listing USATRANASDAQHealthcareQuality Compounder

Atara Biotherapeutics Inc(ATRA) Stock Analysis | Healthcare

USD --+0.00%
Reward72High
Risk39Moderate
75%Data
Revenue down 65% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 64.49M
Reward Ratingⓘ72 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ39 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ATRA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Atara Biotherapeutics Inc?

engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.

AI Brief Pro

The brief on Atara Biotherapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Atara Biotherapeutics Inc?

engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 64.49M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: High (72)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.32
Insider Activity
12M windowMixed
Shares soldShares bought
0-3months
16,094 shares
$39k
1104,166 shares
$1000k
3-6months
15,062 shares
$41k
0
6-9months
11326,201 shares
$3.3M
1507,407 shares
$4.7M
9-12months
180,554 shares
$489k
0